NRX Pharmaceuticals Inc (NRXP)

[Bob1968]

I sent an email to the NRX "Right to Try" page to see if they are still allowing its use. We shall see.

All this is so strange and conflicting because right at the beginning of 2022 we were informed of this:

NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge

-A Southwestern hospital has reported safety data collected under the Federal Right to Try law indicating that 16 of 19 patients (84%) with COVID-19 respiratory failure treated with ZYESAMI® by Dec 31, 2021 have survived the ICU.

-No Serious Adverse Events were reported

-Patients were treated during the Omicron Surge

-Patients were treated at first onset of respiratory failure after exhausting remdesivir and other approved therapies

-Data are being included provided by NRx to FDA in support of ongoing application to FDA for Emergency Use Authorization

https://www.prnewswire.com/news-releases/nrx-receives-initial-report-of-patient-safety-and-survival-from-right-to-try-use-of-zyesami-aviptadil-during-omicron-surge-301468389.html

So, the question is, what suddenly caused the positive results to flip to negative? Will this be addressed during the shareholders meeting?

This was sent out by NRX: (In part)

You are cordially invited to attend the 2022 Annual Meeting of Stockholders of NRx Pharmaceuticals, Inc. to be held on July 18, 2022, at 11:00 a.m., local time, in virtual format at:
https://www.cstproxy.com/nrxpharma/2022